1. Stevenson LW, Child JS, Laks H, Kern L. Incidence and significance of early pericardial effusions after cardiac surgery. Am J Cardiol. 1984;54:848-51.
 
2. Warner LL, Hoffman JR, Baraff LJ. Prognostic significance of field response in out-of-hosptial ventricular fibrillation. Chest. 1985;87:848-851.
 
3. Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. Circulation. 1986;74:1303-8.
 
4. Stevenson LW, Fowler MB, Schroeder JS, Stevenson WG, Dracup KA, Fond V.  Poor survival of patients with idiopathic cardiomyopathy considered too well for transplantation. Am J Med. 1987;83:871-6.
 
5. Stevenson LW, Bellil D, Grover-McKay M, Brunken RC, Schwaiger M, Tillisch JH, Schelbert HR. Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1987;60:654-8.
 
6. Strauss RH, Stevenson LW, Dadourian BA, Child JS. Predictability of mitral regurgitation detected by Doppler echocardiography in patients referred for cardiac transplantation. Am J Cardiol. 1987;59:892-4.
 
7. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884-8.
 
8. Stevenson LW, Dracup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol. 1989;63:461-4.
 
9. Stevenson LW, Brunken RC, Belil D, Grover-McKay M, Schwaiger M, Schelbert HR, Tillisch JH. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. J Am Coll Cardiol. 1990;15:174-80.
 
10. Stevenson LW, Tillisch JH, Hamilton M, Luu M, Chelimsky-Fallick C, Moriguchi J, Kobashigawa J, Walden J. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol. 1990; 66:1348-54.
 
11. Stevenson LW, Sietsema K, Tillisch JH, Lem V, Walden J, Kobashigawa JA, Moriguchi J. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. Circulation. 1990;81:78-85.
 
12. Walden JA, Stevenson LW, Dracup K, Hook JF, Moser DK, Hamilton M, Fonarow GC.  Extended comparison of quality of life between stable heart failure patients and heart transplant recipients. J Heart Lung Transplant. 1994;13:1109-18.
 
13. Steimle AE, Stevenson LW, Chelimsky-Fallick C, Fonarow GC, Hamilton MA, Moriguchi JD, Kartashov A, Tillisch JH. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997; 96:1165-72.
    
    

15.  ESCAPE Investigators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005; 294(13):1625-33.

16.  Stevenson LW, Desai A. Selecting patients for discussion of the ICD as primary prevention for sudden death in heart failure. Journal of Cardiac Failure 2006; 12(6);407-12. 

17.  Zile MR, Bennett TD, St. John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda, Jr. JM, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC.  Transition from Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiologic Insights Obtained From Continuous Monitoring of Intracardiac Pressures.  Circulation. 2008;118;14:1433-41.

 


18.  Russo MJ, Gelijns A, Stevenson LW, Sampat B, Aaronson KD, Renlund DG, Ascheim DD, Hong KN, Oz MC, Moskowitz AJ, Rose EA, Miller LW.  The cost of medical management in advanced heart failure during the final two years of life.  J Card Fail 2008;14;8:651-8.

 


19.  Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnica JW, Abraham WT, Kasper EK, Rogers JG, Califf RM, Schramm EE, O'Connor CM. Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol 2008;52(21):1702-8.


20.  Palardy M, Stevenson LW, Gudaye T, Hamilton MA, Bourge RC, DiSalvo TG, Elkayam U, Hill JA, Reimold SC.  Reduction in mitral regurgitation during therapy guided by measured filling pressures in the ESCAPE trial.  Circulation: Heart Fail 2009, in press.

 

Masiakos PT, MacLaughlin DT, Teixeira J, Maheswaran S, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK. Human Ovarian Cancer,  Cell Lines and Primary Ascites Cells, Express the Human MIS Type II Receptor, Bind, and are Responsive to MIS.  Clin Cancer Res 1999; 5(11):3488-99.

Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT.  Recombinant Human MIS inhibits Long Term Growth of MISRII directed Transgenic Mouse Ovarian Cancers in vivo.   Clin Cancer Res 2006; 12(5):1593-1598. 

Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK.  Mullerian Inhibiting Substance regulates its receptor/Smad signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression.   Development 2006;133:2359-2369.

Pieretti-Vanmarcke, R, Donahoe PK, Pearsall L, Connolly DC, Dinulescu D, Halpern EF, Seiden M, MacLaughlin DT.  MIS Enhances Subclinical Doses of Chemotherapeutic Agents to Inhibit Human and Mouse Ovarian Cancer.    PNAS 2006; 103(46); 17426-17431. 

Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, MacLaughlin DT, Donahoe PK.  Ovarian cancer side population defines cells with stem cell-like charactersitcs and MIS responsiveness.     PNAS 2006; 103(30):11154-11159.

Szotek, P; Chang, H L; Brennand, K; Fujino, A; Pieretti-Vanmarcke, R; Lo Ceslo, C; Dombkowski, D; Preffer, F; Cohen, K; Teixeira, J; Donahoe, P; Normal Ovarian Surface Epithelial Label Retaining Cells Exhibit Stem/Progenitor Cell Characteristics, PNAS 105(34); 12469-12473, August 2008 

Akihiro Fujino, Nelson A. Arrango, Yong Zhan, Thomas F. Manganaro, Xianlin Li, David T. MacLaughlin, Patricia K. Donahoe. Cell migration and activated PI3K/AKT-directed elongationin the developing rat Mullerian duct. Developmental Biology Dev Biol 2009 325(2):351-62. [Epub 2008 Nov 5. ahead of print] 

Nathan Case Study Seminar Readings October 30, 2008

2.  Nathan, D. M., D. E. Singer, et al. (1986). “Retinopathy in older type II diabetics: association with glucose control.” Diabetes 35(7): 797-801.
read article

4.  Nathan, D. M., J. E. Godine, et al. (1984). “Ice cream in the diet of insulin-dependent diabetic patients.” JAMA 251(21): 2825-2827.
read article

5.  Diabetes Control and Complications Trial Research Group. (1993). “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.” N Engl J Med 329: 977-986.
read article

6.  Meigs, J. B., D. M. Nathan, et al. (1998). “Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance.” Ann Intern Med 128(7): 524-533.
read article

7.  Diabetes Prevention Program Research Group. (2002). “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.” N Engl J Med 346(6): 393-403.
read article

8. Nathan DM, Cleary PA, Backlund J-YC, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B.(2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes mellitus. N Engl J Med  353: 2643-2653.
read article

9. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetelogia 2006, 49:1711-1721. (Published simultaneously in Diabetes Care 2006; 29: 1963-72.
read article

10. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c Derived Average Glucose (ADAG) Study Group. Translating the A1c assay into estimated average glucose values. Diabetes Care 2008; 31:1473-8.
read article

Event Type: Summer Session
Description:

• All Students - Final Presentations in three rooms simultaneously

Location: Ledge Conference rooms 4-002H, E, and G as assigned
Open to Public? No

Event Type: Summer Session
Description:

• 2:30pm "Important Presentation Skills" - Gary Curhan, MD and Naomi Fisher, MD
• 3:30pm Journal Club - (two simultaneous student-led sessions on critical reading skills)

Location: Brigham & Women's Hospital, Carrie Hall.  At 3:30pm, group separates for Journal Club
Open to Public? No

Event Type: Summer Session
Description:

• 2:30pm "Careers in Academia and Industry" - Ann Taylor, MD
• 3:30pm Journal Club - (two simultaneous student-led sessions on critical reading skills)

Location: Brigham & Women's Hospital, Carrie Hall.  At 3:30pm, group divides into two
Open to Public? No

Event Type: Summer Session
Description:

• 2:30pm Journal Club - (two simultaneous student-led sessions on critical reading skills)
• 3:30pm "Research Studies Requiring Lifestyle Modifications" - Paul Conlin, MD

Location: Brigham & Women's Hospital Carrie Hall Conference Room (divided in two groups). At 3:30pm, group assembles together for featured speaker
Open to Public? No

Event Type: Summer Session
Description:

• 2:30pm "Moving between Observational Epidemiology and Full-Scale Clinical Trials" - Ravi Thadhani, MD
• 3:30pm Journal Club - (two simultaneous student-led sessions on critical reading skills)

Location: One Brigham Circle, Ledge conf. rm 4-002B.  At 3:30pm, half the group moves to 4-002H
Open to Public? No

Event Type: Summer Session
Description:

• 2:30pm "From Classroom Physiology to Clinical Treatment" - Lynn Stevenson, MD
• 3:30pm Journal Club - (two simultaneous student-led sessions on critical reading skills)

Location: One Brigham Circle, Ledge conf. rm 4-002E/G.  At 3:30pm, half the group moves to 4-002H
Open to Public? No

Event Type: Summer Session
Description:

• 2:30pm "Human studies, Ethics and Normal Volunteers" - Corinne Welt, MD
  
• 3:30pm Journal Club - (two simultaneous student-led sessions on critical reading skills)

Location: One Brigham Circle, Ledge conf. rm 4-002B.  At 3:30pm half the group moves to 4-002H
Open to Public? No